Syncona's Portfolio Company Outlines Positive Clinical Trial Data for Retinitis Pigmentosa Therapy

04:08 AM EDT, 09/21/2026 (MT Newswires) -- Syncona's (SYNC.L) portfolio company, Beacon Therapeutics, delivered positive topline results from its phase II/III Vista clinical trial of laru-zova as a treatment of the blinding condition X-linked retinitis pigmentosa. The study acheieved its US Food and Drug Administration-endorsed primary endpoint demonstrating statistically significant low luminesce visual acuity in patients, according to a Monday filing. Laru-zova also exhibited a favorable safety and tolerability profile, the London-listed life science investor said. Beacon will use the outcome to discuss the submission of a rolling biologics license application with global regulators in 2026.